Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by DryBoneson Nov 16, 2019 6:14pm
172 Views
Post# 30360899

RE:RE:What is the Potential Upside

RE:RE:What is the Potential UpsideThe  potential upside is little, but more importantly, shortlived.   Poorly prepared canadian companies that go on the Naz with litttle or no strategy get CLOBBERED.  Witness Oncolytics, one of a long line of failures:  after a reverse taking it to $10, it got nailed by shorters and taken down to $1.  A buck and you are fcked.  

If you are actually an investor, and not just one of the legions of paid pumpers infesting this board, then be wary, be afraid, be scared, have nightmares. This is shitz-on-a-stick sold as ice cream.   Management treats shareholders even worse.  Run, run, run.
<< Previous
Bullboard Posts
Next >>